Transhepatic therapies for metastatic uveal melanoma

Seminars in Interventional Radiology

Volumn 30, Issue 1, 2013, Pages 39-48

  Eschelman, David J ^a,b,c   Gonsalves, Carin F ^a,b,c   Sato, Takami ^d  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^b Division of Interventional Radiology   (United States)

^c Department of Radiology ^*  (United States)

^d THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

chemoembolization; immunoembolization; liver metastases; radioembolization; uveal melanoma

Indexed keywords

EID: 84874393511     PISSN: 07399529     EISSN: 10988963     Source Type: Journal    
DOI: 10.1055/s-0033-1333652     Document Type: Article

References (48)

1. Singh A. D., Turell M. E., Topham A. K. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology: 2011; 118 9 1881 1885
2. Sato T. Locoregional management of hepatic metastasis from primary uveal melanoma. Semin Oncol: 2010; 37 2 127 138
3. Shields C. L., Shields J. A. Ocular melanoma: relatively rare but requiring respect. Clin Dermatol: 2009; 27 1 122 133
4. Shields C. L., Furuta M., Thangappan A., et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol: 2009; 127 8 989 998
5. Damato B., Coupland S. E. A reappraisal of the significance of largest basal diameter of posterior uveal melanoma. Eye (Lond): 2009; 23 12 2152 2160; quiz 2161-2162
6. van den Bosch T., van Beek J. GM, Vaarwater J., et al. Higher percentage of FISH-determined monosomy 3 and 8q amplification in uveal melanoma cells relate to poor patient prognosis. Invest Ophthalmol Vis Sci: 2012; 53 6 2668 2674
7. Prescher G., Bornfeld N., Hirche H., Horsthemke B., Jöckel K. H., Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet: 1996; 347 9010 1222 1225
8. Onken M. D., Worley L. A., Char D. H., et al. Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology: 2012; 119 8 1596 1603
9. Kolata G. A game changer in revealing a cancer's prognosis. New York Times, July 9, 2012
10. Spagnolo F., Caltabiano G., Queirolo P. Uveal melanoma. Cancer Treat Rev: 2012; 38 5 549 553
11. Hsueh E. C., Essner R., Foshag L. J., Ye X., Wang H. J., Morton D. L. Prolonged survival after complete resection of metastases from intraocular melanoma. Cancer: 2004; 100 1 122 129
12. Aoyama T., Mastrangelo M. J., Berd D., et al. Protracted survival after resection of metastatic uveal melanoma. Cancer: 2000; 89 7 1561 1568
13. Bedikian A. Y., Legha S. S., Mavligit G., et al. Treatment of uveal melanoma metastatic to the liver: a review of the M. D. Anderson Cancer Center experience and prognostic factors. Cancer: 1995; 76 9 1665 1670
14. Carrasco C. H., Wallace S., Charnsangavej C., Papadopoulos N. EJ, Patt Y. Z., Mavligit G. M. Treatment of hepatic metastases in ocular melanoma. Embolization of the hepatic artery with polyvinyl sponge and cisplatin. JAMA: 1986; 255 22 3152 3154
15. Mavligit G. M., Charnsangavej C., Carrasco C. H., Patt Y. Z., Benjamin R. S., Wallace S. Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA: 1988; 260 7 974 976
16. Sato T., Nathan F. E., Berd D., Sullivan K., Mastrangelo M. J. Lack of effect from chemoembolization for liver metastasis from uveal melanoma. Proc Am Soc Clin Oncol: 1995; 14 415
17. Patel K., Sullivan K., Berd D., et al. Chemoembolization of the hepatic artery with BCNU for metastatic uveal melanoma: results of a phase II study. Melanoma Res: 2005; 15 4 297 304
18. Monsky W. L., Kim I., Loh S., et al. Semiautomated segmentation for volumetric analysis of intratumoral Ethiodol uptake and subsequent tumor necrosis after chemoembolization. AJR Am J Roentgenol: 2010; 195 5 1220 1230
19. Vogl T., Eichler K., Zangos S., et al. Preliminary experience with transarterial chemoembolization (TACE) in liver metastases of uveal malignant melanoma: local tumor control and survival. J Cancer Res Clin Oncol: 2007; 133 3 177 184
20. Sharma K. V., Gould J. E., Harbour J. W., et al. Hepatic arterial chemoembolization for management of metastatic melanoma. AJR Am J Roentgenol: 2008; 190 1 99 104
21. Dayani P. N., Gould J. E., Brown D. B., Sharma K. V., Linette G. P., Harbour J. W. Hepatic metastasis from uveal melanoma: angiographic pattern predictive of survival after hepatic arterial chemoembolization. Arch Ophthalmol: 2009; 127 5 628 632
22. Cantore M., Fiorentini G., Aitini E., et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori: 1994; 80 1 37 39
23. Huppert P. E., Fierlbeck G., Pereira P., et al. Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol: 2010; 74 3 e38 e44
24. Gupta S., Bedikian A. Y., Ahrar J., et al. Hepatic artery chemoembolization in patients with ocular melanoma metastatic to the liver: response, survival, and prognostic factors. Am J Clin Oncol: 2010; 33 5 474 480
25. Fiorentini G., Aliberti C., Del Conte A., et al. Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In Vivo: 2009; 23 1 131 137
26. Venturini M., Pilla L., Agostini G., et al. Transarterial chemoembolization with drug-eluting beads preloaded with irinotecan as a first-line approach in uveal melanoma liver metastases: tumor response and predictive value of diffusion-weighted MR imaging in five patients. J Vasc Interv Radiol: 2012; 23 7 937 941
27. Sullivan K. L. Immunoembolization for melanoma. In: Geschwind J. FH, Soulen M. C., eds. Interventional Oncology: Principles and Practice. New York, NY Cambridge University Press: 2008; 311 315
28. Yamamoto A., Sato T. Locoregional treatment of malignant hepatic tumors with biologic response modifiers. Surg Oncol Clin N Am: 2008; 17 4 935 955, xii
29. Kanai T., Monden M., Sakon M., et al. New development of transarterial immunoembolization (TIE) for therapy of hepatocellular carcinoma with intrahepatic metastases. Cancer Chemother Pharmacol: 1994; 33 Suppl S48 S54
30. Yoshida T., Sakon M., Umeshita K., et al. Appraisal of transarterial immunoembolization for hepatocellular carcinoma: a clinicopathologic study. J Clin Gastroenterol: 2001; 32 1 59 65
31. Dranoff G., Jaffee E., Lazenby A., et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A: 1993; 90 8 3539 3543
32. Sullivan K. L., Aoyama T., Sato T., McCue P. Safety of immunoembolization of normal swine liver with human GM-CSF (granulocyte macrophage colony stimulating factor) and Ethiodol. J Vasc Interv Radiol: 2001; 12 S132 S133
33. Sato T., Eschelman D. J., Gonsalves C. F., et al. Immunoembolization of malignant liver tumors, including uveal melanoma, using granulocyte-macrophage colony-stimulating factor. J Clin Oncol: 2008; 26 33 5436 5442
34. Yamamoto A., Chervoneva I., Sullivan K. L., et al. High-dose immunoembolization: survival benefit in patients with hepatic metastases from uveal melanoma. Radiology: 2009; 252 1 290 298
35. Speiser D. E., Miranda R., Zakarian A., et al. Self antigens expressed by solid tumors do not efficiently stimulate naive or activated T cells: implications for immunotherapy. J Exp Med: 1997; 186 5 645 653
36. Dow S. W., Elmslie R. E., Willson A. P., Roche L., Gorman C., Potter T. A. In vivo tumor transfection with superantigen plus cytokine genes induces tumor regression and prolongs survival in dogs with malignant melanoma. J Clin Invest: 1998; 101 11 2406 2414
37. Eschelman D. J., Gonsalves C. F., Terai M., et al. The results of a randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor (GM-CSF) in uveal melanoma patients with hepatic metastasis. J Clin Oncol: 2011; 29 544s
38. Parmiani G., Castelli C., Pilla L., Santinami M., Colombo M. P., Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol: 2007; 18 2 226 232
39. Kennedy A. S., Nutting C., Jakobs T., et al. A first report of radioembolization for hepatic metastases from ocular melanoma. Cancer Invest: 2009; 27 6 682 690
40. Gonsalves C. F., Eschelman D. J., Sullivan K. L., Anne P. R., Doyle L., Sato T. Radioembolization as salvage therapy for hepatic metastasis of uveal melanoma: a single-institution experience. AJR Am J Roentgenol: 2011; 196 2 468 473
41. Klingenstein A., Haug A. R., Zech C. J., Schaller U. C. Radioembolization as locoregional therapy of hepatic metastases in uveal melanoma patients. Cardiovasc Intervent Radiol: 2012;; April 21 (Epub ahead of print)
42. Van de Wiele C., Maes A., Brugman E., et al. SIRT of liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging: 2012; 39 10 1646 1655
43. Leyvraz S., Spataro V., Bauer J., et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol: 1997; 15 7 2589 2595
44. Peters S., Voelter V., Zografos L., et al. Intra-arterial hepatic fotemustine for the treatment of liver metastases from uveal melanoma: experience in 101 patients. Ann Oncol: 2006; 17 4 578 583
45. Alexander H. R. Jr, Butler C. C. Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J: 2010; 16 2 132 141
46. Alexander H. R. Jr, Libutti S. K., Pingpank J. F., et al. Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res: 2003; 9 17 6343 6349
47. Pingpank J. F., Hughes M. S., Faries M. B., et al. A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. J Clin Oncol: 2010; 28 18s
48. Zager J., Nutting C. Chemosaturation therapy with percutaneous hepatic perfusions of melphalan versus standard of care in patients with hepatic metastases from melanoma: A randomized multicenter phase 3 study. J Vasc Interv Radiol: 2012; 23 S3